ライフサイエンスコーパス: paclitaxel

1 d Abraxane (nanoparticle albumin-bound (nab)-paclitaxel).

2 pembrolizumab/carboplatin/(paclitaxel or nab-paclitaxel).

3 inhibition sensitized the resistant cells to paclitaxel.

4 explain the phloem-specific accumulation of paclitaxel.

5 nal cohort treated with gemcitabine plus nab-paclitaxel.

6 basal keratinocytes following treatment with paclitaxel.

7 CI, 6.6 to 8.8 months) for carboplatin plus paclitaxel.

8 cisplatin plus FU and 45 to carboplatin plus paclitaxel.

9 bevacizumab, or atezolizumab/carboplatin/nab-paclitaxel.

10 he frontline chemotherapeutics cisplatin and paclitaxel.

11 tuzumab accelerates the cytotoxic effects of paclitaxel.

12 nhibitor, buthionine sulphoximine (BSO), and paclitaxel.

13 ent, 606 with NAB-paclitaxel and 600 with sb-paclitaxel.

14 uropathy (CIPN) is a major adverse effect of paclitaxel.

15 re and mitotic death induced by low doses of paclitaxel.

16 n patients with early BC as compared with sb-paclitaxel.

17 n patients treated with gemcitabine plus nab-paclitaxel.

18 ols under selection in media with or without paclitaxel.

19 95% CI, 42.1% to 74.4%) for carboplatin plus paclitaxel.

20 xus stem barks can be used for extraction of paclitaxel.

21 s) or investigator's choice of chemotherapy (paclitaxel 100 mg/m(2) for at least 60 min once per week

22 y 1 and day 15 of every 28-day cycle and nab-paclitaxel 100 mg/m(2) of body surface area intravenousl

23 schedule of 3 weeks on and 1 week off of NAB-paclitaxel (100 mg/m(2) [arm B] or 125 mg/m(2) [arm D])

24 avenous atezolizumab (1200 mg) on day 1, nab-paclitaxel (100 mg/m(2)) on days 1, 8, and 15, and carbo

25 urve 6 mg/mL per min every 3 weeks] plus nab-paclitaxel [100 mg/m(2) intravenously every week]) or ch

26 he mortality difference was not significant; paclitaxel (12.8%) versus nonpaclitaxel devices (15.5%;

27 PSN improved much faster under NAB-paclitaxel 125 mg/m(2) compared with NAB-paclitaxel 150

28 signed in a 1:1 ratio to 12 times weekly NAB-paclitaxel 150 mg/m(2) (after study amendment, 125 mg/m(

29 NAB-paclitaxel 125 mg/m(2) compared with NAB-paclitaxel 150 mg/m(2).

30 atients per arm): a biweekly schedule of NAB-paclitaxel (150 mg/m(2) [arm A] or 125 mg/m(2) [arm C])

31 amide for stage I-III breast cancer received paclitaxel 175 mg/m(2) every 2 weeks.

32 lowed by four cycles of carboplatin AUC5 and paclitaxel 175 mg/m(2) given intravenously), by use of a

33 er the curve [AUC]5 or AUC6) and intravenous paclitaxel (175 mg/m(2) by body surface area) on day 1 o

34 ze of six patients) to receive six cycles of paclitaxel (175 mg/m(2)) and carboplatin (area under the

35 under the concentration v time curve 6) and paclitaxel (175 mg/m(2)) versus chemotherapy plus concur

36 eived neoadjuvant treatment with intravenous paclitaxel (200 mg/m(2)) and carboplatin (area under cur

37 platin (area under the curve, 5; day 1) plus paclitaxel 80 mg/m(2) (days 1, 8, and 15) every 28 days

38 r study amendment, 125 mg/m(2)) or weekly sb-paclitaxel 80 mg/m(2) followed in both arms by four time

39 ) on day 1 and intravenous dose-fractionated paclitaxel (80 mg/m(2) by body surface area) on days 1,

40 tin (AUC2) and intravenous dose-fractionated paclitaxel (80 mg/m(2) by body surface area) on days 1,

41 6 mg/mL per min intravenously) on day 1 and paclitaxel (80 mg/m(2) intravenously) on days 1, 8, and

42 a significantly better iDFS compared with sb-paclitaxel (84.0% v 76.3%; hazard ratio, 0.66; 95% CI, 0

43 of the potent broad-spectrum anticancer drug paclitaxel (a.k.a. Taxol) that is stable in cell culture

44 Taxol (paclitaxel), a plant-derived anticancer drug, has been a

45 ndered breast cancer cells more sensitive to paclitaxel, a chemotherapeutic agent that induces ER str

46 ow that palbociclib, a CDK4/6 inhibitor, and paclitaxel, a microtubule inhibitor, synergize with the

47 nomic instability and enhance sensitivity to paclitaxel, a microtubule stabilizer and anti-tumor drug

48 zumab plus bevacizumab plus carboplatin plus paclitaxel (ABCP) versus the standard-of-care bevacizuma

49 of routine peg-filgrastim during dose-dense paclitaxel according to a prespecified algorithm seems t

50 NAB-paclitaxel administered at either 100 and 125 mg/m(2) in

51 Carboplatin and paclitaxel administered every 3 weeks is standard-of-car

52 PB displays a strong synergistic effect with paclitaxel against growth-inhibitory action of a patient

53 he FDA/EMEA approved dose of gemcitabine-nab-paclitaxel along-with ATRA (45 mg/m(2) orally, days 1-15

54 l (iDFS) events were reported (143 in the sb-paclitaxel and 100 in the NAB-paclitaxel arm).

55 and overall survival with dose-dense weekly paclitaxel and 3-weekly carboplatin.

56 ecutive EC patients treated with carboplatin/paclitaxel and 41.4Gy between 2009 and 2018.

57 ly assigned to receive atezolizumab plus nab-paclitaxel and 451 were assigned to receive placebo plus

58 with detection limits of 1.5 x 10(-8) M for paclitaxel and 5 x 10(-9) M for cyclophosphamide in bloo

59 206 patients started treatment, 606 with NAB-paclitaxel and 600 with sb-paclitaxel.

60 nt with atezolizumab in combination with nab-paclitaxel and anthracycline-based chemotherapy signific

61 litis); two were considered to be related to paclitaxel and carboplatin (general physical health dete

62 designed substrates were utilized for TDM of paclitaxel and cyclophosphamide in blood serum.

63 ages of synchronized interstitial therapy of paclitaxel and everolimus for post-surgical tumor contro

64 Combination interstitial therapy of both paclitaxel and everolimus significantly reduced GBM grow

65 ching release kinetics (~3% per day) of both paclitaxel and everolimus to maintain a fixed combinatio

66 The strong synergism seen with paclitaxel and everolimus was then explored in vivo.

67 Paclitaxel and everolimus were separately formulated int

68 ance to apoptosis-inducing agents, including paclitaxel and HA14-1.

69 lencing improves the proapoptotic effects of paclitaxel and induces mitotic abnormalities, including

70 ficial femoral-popliteal artery disease with paclitaxel and nonpaclitaxel devices using a multicenter

71 tially rescued to reduce CIN by low doses of paclitaxel and nucleoside supplementation, respectively.

72 In addition, tumors from paclitaxel and PFL-treated mice showed reduced HER2 and

73 gastric cancer cells toward different drugs, paclitaxel and sodium dichloroacetate, was distinguished

74 s where trastuzumab is administered prior to paclitaxel and suggests trastuzumab accelerates the cyto

75 The Adjuvant Paclitaxel and Trastuzumab trial was designed to address

76 es of chemotherapy involving carboplatin and paclitaxel, and an Eastern Cooperative Oncology Group st

77 group were considered related to trebananib, paclitaxel, and carboplatin (lung infection and neutrope

78 placebo in combination with carboplatin and paclitaxel, and continued as monotherapy if carboplatin

79 miR-522-3p sensitized the resistant cells to paclitaxel, and its downregulation desensitized the pare

80 peripheral neuropathy (CIPN), agents such as paclitaxel are known to elicit chronic neuropathic pain

81 arm (62%) compared with the carboplatin plus paclitaxel arm (36%; P = .016).

82 (143 in the sb-paclitaxel and 100 in the NAB-paclitaxel arm).

83 with mFOLFIRINOX (Arm 1) or gemcitabine/nab-paclitaxel (Arm 2).

84 -free survival when added to carboplatin and paclitaxel as first-line therapy in advanced epithelial

85 Chemotherapy comprised of nab-paclitaxel at 125 mg/m(2) every week for 12 weeks follow

86 nal options are atezolizumab/carboplatin/nab-paclitaxel, atezolizumab/carboplatin/paclitaxel/bevacizu

87 ent meta-analysis of heterogeneous trials of paclitaxel-based balloons and stents reported that they

88 We have synthesised photoswitchable paclitaxel-based microtubule stabilisers, whose binding

89 rd-of-care bevacizumab plus carboplatin plus paclitaxel (BCP) in chemotherapy-naive patients with non

90 If patients discontinued carboplatin and paclitaxel before progression, they could continue velip

91 oplatin/pemetrexed, atezolizumab/carboplatin/paclitaxel/bevacizumab, or atezolizumab/carboplatin/nab-

92 tin/nab-paclitaxel, atezolizumab/carboplatin/paclitaxel/bevacizumab, platinum-based two-drug combinat

93 Paclitaxel biodisposition was evaluated for two formulat

94 to investigate the effect of formulation on paclitaxel biodistribution following intravenous adminis

95 gations indicated that TmMYB3 is involved in paclitaxel biosynthesis by activating the expression of

96 roteomic approach, and the role of TmMYB3 in paclitaxel biosynthesis was investigated.

97 Ten key enzymes involved in paclitaxel biosynthesis were identified, most of which a

98 a role in the transcriptional regulation of paclitaxel biosynthesis, and may explain the phloem-spec

99 hole stem and the stem tissue-specificity of paclitaxel biosynthesis-related enzymes remain largely u

100 mMYB3 and partial promoter sequences of five paclitaxel biosynthesis-related genes were isolated.

101 s carriers increases the water-solubility of paclitaxel by 32,000-fold.

102 ys increase drug resistance to cisplatin and paclitaxel by reducing their ability to damage DNA and m

103 In the MC38 model, paclitaxel/carboplatin did not result in an appreciable

104 shown to induce immunogenic cell death, and paclitaxel/carboplatin, reported to cause immunogenicall

105 ng agent in combination with gemcitabine-nab-paclitaxel chemotherapy using a two-step adaptive contin

106 bicin (Cl66-Dox), or Cl66 cells resistant to paclitaxel (Cl66-Pac).

107 Paclitaxel coated balloons (PCBs) are a promising non-im

108 sed risk of death associated with the use of paclitaxel-coated angioplasty balloons and stents in low

109 controlled trials (RCTs) of femoropopliteal paclitaxel-coated balloon and stent intervention identif

110 after plain balloon angioplasty (12.6%) and paclitaxel-coated balloon angioplasty (9.6%; HR=0.84 [95

111 s; plain balloon angioplasty (N=2104) versus paclitaxel-coated balloon angioplasty (N=3543), bare-met

112 on survival after coronary intervention with paclitaxel-coated balloons from randomized controlled tr

113 On the contrary, use of coronary paclitaxel-coated balloons was associated with a trend t

114 in limb revascularization compared with non-paclitaxel-coated devices and were rapidly accepted into

115 sed risk of death associated with the use of paclitaxel-coated devices in the superficial femoral art

116 heral artery disease received treatment with paclitaxel-coated or uncoated endovascular devices, the

117 d trial (Randomized Trial of IN.PACT Admiral Paclitaxel-Coated Percutaneous Transluminal Angioplasty

118 cer were randomly assigned to receive weekly paclitaxel combined with trastuzumab plus lapatinib (THL

119 The primary end point was the rate of paclitaxel completion within 7 weeks from cycle 1 day 1

120 The RNA-paclitaxel complex is structurally rigid and stable, dem

121 hese data indicate that the chemotherapeutic paclitaxel concurrently affects the gut microbiome, colo

122 mental study of cancer drugs (prodigiosin or paclitaxel) conjugated to Luteinizing Hormone-Releasing

123 Paclitaxel-containing devices (PTXDs) significantly redu

124 indings do not support routine use of weekly paclitaxel-containing regimens in the management of newl

125 assigned to receive placebo plus carboplatin-paclitaxel (control group).

126 Atezolizumab plus carboplatin and nab-paclitaxel could be a potential neoadjuvant regimen for

127 inical formulations, Cremophor EL-formulated paclitaxel (crPTX) and Abraxane (nanoparticle albumin-bo

128 -filgrastim was administered in only 4.3% of paclitaxel cycles.

129 ndently adjudicated prospective studies of a paclitaxel DCB (n = 1,837) and uncoated percutaneous tra

130 t-level meta-analysis demonstrates that this paclitaxel DCB is safe.

131 In this meta-analysis, the use of paclitaxel DCBs for treatment of coronary artery disease

132 Paclitaxel decreased the abundance of Akkermansia mucini

133 sis mortality was significantly lower in the paclitaxel device group (8.5%) compared with the nonpacl

134 tent claudication, mortality was lower after paclitaxel device use (1.6%) compared with nonpaclitaxel

135 after nonpaclitaxel (N=1113/4149, 26.8%) and paclitaxel device use (N=1113/4227, 26.3%).

136 mbination of trebananib plus carboplatin and paclitaxel did not produce new safety signals.

137 ing drugs such as methotrexate, doxorubicin, paclitaxel, docetaxel, irinotecan and its important meta

138 A survival analysis stratified nominal paclitaxel dose by low, mid, and upper terciles; mean do

139 No fatalities are observed at a paclitaxel dose equal to the reported LD(50).

140 Survival time by paclitaxel dose tercile was analyzed with adjustment of

141 ts were performed to explore correlations of paclitaxel dose with long-term mortality.

142 prospective clinical trials confirm that the paclitaxel drug-coated balloon (DCB) (IN.PACT Admiral, M

143 Conclusion At 2 years after paclitaxel drug-coated balloon (DCB) angioplasty, primar

144 Background Paclitaxel drug-coated balloon (DCB) catheter angioplast

145 Paclitaxel drug-coated balloons and drug-eluting stents

146 (Paclitaxel-Eluting Balloon Angioplasty With Provisional

147 mized Evaluation of the Zilver PTX Stent vs. Paclitaxel-Eluting Balloons for Treatment of Symptomatic

148 inol Stent Versus Systematic Implantation of Paclitaxel-Eluting Stent for the Treatment of Femoropopl

149 similar after bare-metal stenting (9.8%) and paclitaxel-eluting stenting (8.8%; HR=0.93 [95% CI, 0.62

150 =3543), bare-metal stenting (N= 2045) versus paclitaxel-eluting stents (N=684), and combined paclitax

151 use death between PCI using first-generation paclitaxel-eluting stents and CABG.

152 ry intervention (PCI) using first-generation paclitaxel-eluting stents with coronary artery bypass gr

153 cancer treatment are Tamoxifen, Trastuzumab, Paclitaxel, etc.

154 der the curve [AUC]5 or AUC6 and 175 mg/m(2) paclitaxel every 3 weeks), group 2 (carboplatin AUC5 or

155 e [AUC]5 or AUC6 and 175 mg/m(2) intravenous paclitaxel every 3 weeks), group 2 (carboplatin AUC5 or

156 Interestingly, the development of paclitaxel-evoked mechanical allodynia was attenuated by

157 determine if there is a correlation between paclitaxel exposure and mortality by conducting an indep

158 s, there was no correlation between level of paclitaxel exposure and mortality.

159 tezolizumab versus placebo combined with nab-paclitaxel followed by doxorubicin plus cyclophosphamide

160 rate compared with weekly solvent-based (sb) paclitaxel followed by epirubicin plus cyclophosphamide

161 chemotherapy (FOLFIRINOX or gemcitabine/nab-paclitaxel) followed by chemoradiation (standard group)

162 homolog of tubulin); 5) is competitive with paclitaxel for binding to tubulin but not with vinblasti

163 that Intralipid reduces the cytotoxicity of paclitaxel for human monocytic cells, but not for breast

164 Herein we evaluated paclitaxel for interstitial therapy, investigating the e

165 ermodynamic stability to solubilize and load paclitaxel for targeted cancer therapy.

166 tabine plus nanoparticle albumin-bound (NAB) paclitaxel (GA) significantly improved survival compared

167 is a common side effect associated with nab-paclitaxel gemcitabine (Nab-Gem) therapy.

168 itor, atezolizumab, with carboplatin and nab-paclitaxel given as neoadjuvant treatment before surgica

169 t 4 years, overall patients treated with NAB-paclitaxel had a significantly better iDFS compared with

170 months to not reached) for carboplatin plus paclitaxel (hazard ratio, 2.00; 95% CI, 1.15 to 3.47; P

171 nt-derived pancreatic adenocarcinoma, PD002: paclitaxel (IC(50): 1.25 muM) inhibits growth of PD002 a

172 bilization of microtubule cytoskeleton using Paclitaxel improved intraventricular conduction defects.

173 entiated tumor growth suppressive effects of paclitaxel in an orthotropic breast cancer model.

174 was not causally related to noncompletion of paclitaxel in any patients.

175 The exposure to paclitaxel in brain, spinal cord, muscle, and skin was l

176 Paclitaxel in combination with 3d had a synergistic anti

177 survival benefit with atezolizumab plus nab-paclitaxel in patients with PD-L1 immune cell-positive d

178 efficacy and safety of atezolizumab plus nab-paclitaxel in patients with unresectable, locally advanc

179 Formulating paclitaxel in PEG-b-PLA micelles, as Genexol-PM(R), perm

180 y of peripheral arterial disease, the use of paclitaxel in peripheral arterial disease and other cond

181 r these compounds overlaps with the site for paclitaxel in the drug-binding pocket.

182 revealed that there is high accumulation of paclitaxel in the phloem.

183 examined the role of TLR9 in CIPN induced by paclitaxel in WT and Tlr9 mutant mice of both sexes.

184 cells and completely restored sensitivity to paclitaxel, in vitro.

185 o, AM1710 produced a sustained inhibition of paclitaxel-induced allodynia in mice.

186 Paclitaxel-induced CIPN caused macrophage infiltration t

187 In contrast, paclitaxel-induced DEGs displayed only a modest overlap

188 ially expressed genes (DEGs) overlapped with paclitaxel-induced DEGs in the DRG and the DH respective

189 multiple bacterial taxa were associated with paclitaxel-induced increases in colon mass, spleen mass,

190 Finally, TLR9 antagonism reduced paclitaxel-induced mechanical allodynia in female nude m

191 ormalin test for acute inflammatory pain and paclitaxel-induced neuropathic pain models during cancer

192 ic depletion causally linked gut microbes to Paclitaxel-induced pain sensitivity and resistance.

193 are respectively sensitive and resistant to Paclitaxel-induced pain, we investigated the involvement

194 s and genetic factors that may predispose to paclitaxel-induced peripheral neuropathy (TIPN).

195 how that MMP-13 dysregulation also underlies paclitaxel-induced peripheral neuropathy in mammals, ind

196 Paclitaxel induces HIF-1-dependent expression of S100A10

197 Paclitaxel induces peripheral neuropathy as a side effec

198 cells; incorporation of the chemotherapeutic paclitaxel into this targeted carrier enhanced cytotoxic

199 H-conjugated drugs (LHRH-prodigiosin or LHRH-paclitaxel) into groups of 4-week-old athymic female nud

200 egative breast cancer, atezolizumab plus nab-paclitaxel is an important therapeutic option in a disea

201 ebananib in combination with carboplatin and paclitaxel is minimally effective in this patient popula

202 stromal-targeting agent with gemcitabine-nab-paclitaxel is safe and tolerable.

203 Paclitaxel is widely used in cancer treatments, but poor

204 Taxol (paclitaxel) is a very widely used anticancer drug, but i

205 Taxol (a brand name for paclitaxel) is widely regarded as among the most famed n

206 onses were also observed against FR-positive paclitaxel (KB-PR) and cisplatin (KB-CR) resistant model

207 aluate the effect of liposome formulation of paclitaxel (L-PTX) on neurotoxicity in-vitro and in-vivo

208 But inherited or acquired resistance to paclitaxel leads to poor response rates in a majority of

209 ss sequencing identified 859 growth loci, 38 paclitaxel loci, 62 interaction loci, and three loci for

210 balloons delivering the antirestenotic agent paclitaxel may improve outcomes.

211 monitor drug release from nanocarriers via a paclitaxel-methylene blue conjugate (PTX-MB) with redox

212 NA nanoparticle covalently loads twenty-four paclitaxel molecules as a prodrug.

213 izumab [n=1] and septic shock related to nab-paclitaxel [n=1]) and one (<1%) patient in the placebo g

214 Intravenous injections of RNA-paclitaxel nanoparticles with specific cancer-targeting

215 oparticles: silver nanoparticles and albumin-paclitaxel nanoparticles.

216 cells in MDA-MB-468 tumors treated with the paclitaxel-nilotinib combination resulted in upregulatio

217 febrile neutropenia but was able to complete paclitaxel on time.

218 Peg-filgrastim was administered after paclitaxel only if patients had had febrile neutropenia

219 s (eg, bevacizumab combined with carboplatin-paclitaxel or carboplatin-gemcitabine) or the most activ

220 Panel recommends pembrolizumab/carboplatin/(paclitaxel or nab-paclitaxel) or chemotherapy.

221 eatment option is pembrolizumab/carboplatin/(paclitaxel or nab-paclitaxel).

222 pembrolizumab/carboplatin/(paclitaxel or nab-paclitaxel) or chemotherapy.

223 y 3 weeks plus chemotherapy (nab-paclitaxel; paclitaxel; or gemcitabine plus carboplatin) or placebo

224 200 mg) every 3 weeks plus chemotherapy (nab-paclitaxel; paclitaxel; or gemcitabine plus carboplatin)

225 and -20% (-33% to -7%) for the comparison of paclitaxel plus ART (64%, 55 to 73; n=138) and bleomycin

226 30% (95% CI -52 to -8) for the comparison of paclitaxel plus ART (week 48 PFS 50%, 32 to 67; n=59) an

227 Week-48 PFS rates were higher in the paclitaxel plus ART arm than in both investigational arm

228 stigational intervention was not shown, with paclitaxel plus ART showing superiority to both oral eto

229 Paclitaxel plus bevacizumab was the only clinically rele

230 itting routine peg-filgrastim use during the paclitaxel portion of the dose-dense doxorubicin-cycloph

231 a combination of siVEGF and standard of care Paclitaxel (PPN-Dual) at reduced doses (< 100 ug/kg) syn

232 d anticancer prodrugs (e.g., camptothecin or paclitaxel prodrug) and hydrophilic glucose oxidase (GOD

233 Systemic in vivo administration of paclitaxel promotes PD-L1 accumulation on the surface of

234 cognition units on the prodigiosin (PGS) and paclitaxel (PTX) drugs and overexpressed LHRH receptors

235 todynamic therapy but stimulates the dimeric paclitaxel (PTX) generating monomeric PTX.

236 Paclitaxel (PTX) is an antineoplastic drug widely used i

237 Recently, we developed such a paclitaxel (PTX) prodrug that targets folate receptors.

238 rmulation in which chemotherapy drugs (e.g., paclitaxel (PTX)) are co-encapsulated with radioluminecs

239 lecules, which have been used to encapsulate paclitaxel (PTX).

240 acid monoconjugated via an ester linkage to paclitaxel (PTX).

241 vel in cancer cells, triggering a release of paclitaxel (PTX).

242 atment significantly increases the amount of paclitaxel reaching the tumor and promotes tumor apoptos

243 combination of MSU-42011 and carboplatin and paclitaxel reduced macrophages in the lung and increased

244 the dose-dense doxorubicin-cyclophosphamide-paclitaxel regimen.

245 n, and oxaliplatin) and gemcitabine plus nab-paclitaxel remain the mainstay of treatment for patients

246 nstrate a novel role of HER2/beta-catenin in paclitaxel resistance and open up new avenues for applic

247 to identify microRNAs (miRNAs) that modulate paclitaxel resistance for use as potential therapeutic t

248 hypothesized that HER2/beta-catenin mediates paclitaxel resistance in breast cancer and suppression o

249 clusion, miR-522-3p attenuated the degree of paclitaxel resistance in vitro through the downregulatio

250 Paclitaxel resistance is a critical challenge in ovarian

251 the parental cells led to the acquisition of paclitaxel resistance, while miR-522-3p inhibited E2F2 e

252 f PFL as a therapeutic option for overcoming paclitaxel resistance.

253 f HER2/beta-catenin signaling could overcome paclitaxel resistance.

254 Paclitaxel-resistant cell lines were established using t

255 The paclitaxel-resistant cells showed stronger E2F2 expressi

256 atment significantly reduced the survival of paclitaxel-resistant cells.

257 xpression of miR-522-3p was downregulated in paclitaxel-resistant cells.

258 plementation may be a therapeutic target for paclitaxel-resistant ovarian cancer.

259 onger survival suggest that carboplatin plus paclitaxel should be considered as a new standard of car

260 that weekly nanoparticle albumin-bound (NAB)-paclitaxel significantly improves the pathologic complet

261 drug-resistant OVASC-1 tumors with cisplatin/paclitaxel (standard-of-care) did not have any statistic

262 blockade of NEK2 activity in the presence of paclitaxel synergistically induced mitotic abnormalities

263 le molecule of the chemotherapeutic compound paclitaxel (Taxol) bound in a central, occluded pocket.

264 bal health scores for those receiving weekly paclitaxel than for those receiving 3-weekly chemotherap

265 e (the investigational arms), or intravenous paclitaxel (the control arm), together with antiretrovir

266 51 were assigned to receive placebo plus nab-paclitaxel (the intention-to-treat population).

267 tionally investigate combination trastuzumab-paclitaxel therapies and identify potential synergistic

268 igands, one copy of miR122, and 24 copies of Paclitaxel to overcome the drug effluxion and chemoresis

269 B designs rely on transferring drugs such as paclitaxel to the arterial vessel using a variety of bio

270 r pathologic complete response rate with NAB-paclitaxel translated into a significantly improved iDFS

271 gate the potential mechanisms of synergy for paclitaxel-trastuzumab combinations.

272 CIPN pain response) tissues from vehicle and paclitaxel treated rats, we performed RNA-sequencing and

273 In paclitaxel-treated mice, a history of AM1710 treatment (

274 In paclitaxel-treated mice, increased fatigue and decreased

275 tion identified excess late mortality in the paclitaxel-treated patients.

276 at the mechanical threshold for allodynia in paclitaxel-treated rats exhibited a robust circadian osc

277 Furthermore, paclitaxel treatment induced de novo diurnal DEGs, sugge

278 hich the combination of ATIP3 deficiency and paclitaxel treatment induces excessive aneuploidy, which

279 Paclitaxel treatment significantly lengthened DRG circad

280 senchymal transition and endow resistance to paclitaxel treatment.

281 d at the peak of neuropathic pain induced by paclitaxel treatment.

282 se model of peripheral neuropathy induced by paclitaxel treatment.

283 ynthesized anticancer drug (prodigiosin) and paclitaxel] using single solvent evaporation technique w

284 signed to receive veliparib plus carboplatin-paclitaxel (veliparib group) and 172 were assigned to re

285 litaxel-eluting stents (N=684), and combined paclitaxel versus nonpaclitaxel devices.

286 of femoral-popliteal occlusive disease with paclitaxel versus nonpaclitaxel devices.

287 against a panel of GBM cell lines in vitro, paclitaxel was found to be effective at nanomolar concen

288 Free paclitaxel was toxic to cell of neuronal origin (IC50 =

289 Paclitaxel was used as the coating agent for all the dru

290 in AUC5 or AUC6 every 3 weeks and 80 mg/m(2) paclitaxel weekly), or group 3 (carboplatin AUC2 and 80

291 in AUC5 or AUC6 every 3 weeks and 80 mg/m(2) paclitaxel weekly), or group 3 (carboplatin AUC2 weekly

292 or group 3 (carboplatin AUC2 and 80 mg/m(2) paclitaxel weekly).

293 up 3 (carboplatin AUC2 weekly and 80 mg/m(2) paclitaxel weekly).

294 continued as monotherapy if carboplatin and paclitaxel were discontinued before progression, in pati

295 trial of cyclophosphamide, doxorubicin, and paclitaxel were queried on their use of supplements at r

296 PEGylated liposomes containing paclitaxel were successfully developed and demonstrated

297 FOLFIRINOX or gemcitabine along with nab-paclitaxel were used in 165 (85%) and 65 (34%) patients,

298 d the combination of tubulin-targeting agent paclitaxel with the BCR-ABL inhibitor nilotinib in MDA-M

299 % [95% CI, 83% to 94%]) completed dose-dense paclitaxel within 7 weeks.

300 00 out of 125 patients completed 4 cycles of paclitaxel without dose delay, the regimen would be cons